The major goal of this training program, which completes its 40th year in May 2015, is to successfully train young investigators in a career in biomedical research pertaining to lymphocyte biology, ranging from cancer immunotherapy to neoplastic transformation. This competitive application is especially timely given that results from Penn-based immunotherapy trials were markedly effective in treating leukemia, a result that contributed to Cancer Immunotherapy being chosen as the 2013 Scientific Breakthrough of the Year by Science Magazine. The Penn training program sits at the nexus of the NCI-designated Abramson Cancer Center and the Institute for Immunology to offer multi-disciplinary training in both basic and translational research related to cancer immunobiology. Drs. Pear (Program Director) and Vonderheide (Program Co-Director) will provide the sustained leadership required for continued development of top-tier cancer immunobiology training at Penn and have an administrative structure that oversees the needs of the training program, assisted by an Internal Executive Committee and an External Advisory Board and complemented by individual research trainee advisory committees. Our training faculty are in multiple departments campus-wide, including the University of Pennsylvania School of Medicine, School of Veterinary Medicine, Children's Hospital of Philadelphia and the Wistar Institute, and have diverse interests that are focused on cancer immunobiology. Common among our trainers is successful mentoring, independent funding, continued productivity and projects relevant to cancer immunobiology. Our 2 predoctoral and 8 postdoctoral trainees are competitively selected and are expected to meet high standards of competence, motivation and perseverance, and have a commitment to a research career in cancer immunobiology. Recruitment of qualified, under-represented minorities is high priority. The training program is anchored in an intensive laboratory experience with a rigorous mentor. The laboratory experience is complemented by basic lecture courses in immunology and related disciplines, advanced seminar courses in various aspects of cancer immunobiology, cancer biology and bioethics, seminars from visiting scientists and Penn faculty, research conferences, workshops and retreats. Programs developed specifically for our trainees include monthly trainee meetings focused on cancer immunobiology, a weekly cancer immunobiology research-in-progress forum, training grant and cancer immunobiology retreats, a visiting scholar/seminar program, and training in the responsible conduct of research. Goals of this training program will be accomplished through two specific aims.
Aim 1 : To support the research and training of young scientists with new or established interests in cancer immunobiology.
Aim 2 : To provide a rich and rigorous training environment in cancer immunobiology that provides multi-disciplinary training in cancer biology and immunology.

Public Health Relevance

This program provides training to develop future leaders in cancer immunobiology research. As a catalyst for developing the next generation of principal investigators, this training program will impact directly on improving cancer treatment, decreasing costs, and most importantly, improving the lives of cancer patients, all of which are directly relevant to public health

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA009140-44
Application #
9547270
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Lim, Susan E
Project Start
1975-07-01
Project End
2020-08-31
Budget Start
2018-09-01
Budget End
2019-08-31
Support Year
44
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Pathology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Bhang, Dong Ha; Kim, Bang-Jin; Kim, Byung Gak et al. (2018) Testicular endothelial cells are a critical population in the germline stem cell niche. Nat Commun 9:4379
Fraietta, Joseph A; Nobles, Christopher L; Sammons, Morgan A et al. (2018) Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558:307-312
Shastrula, Prashanth Krishna; Lund, Peder J; Garcia, Benjamin A et al. (2018) Rpp29 regulates histone H3.3 chromatin assembly through transcriptional mechanisms. J Biol Chem 293:12360-12377
Wilmore, Joel R; Gaudette, Brian T; Gomez Atria, Daniela et al. (2018) Commensal Microbes Induce Serum IgA Responses that Protect against Polymicrobial Sepsis. Cell Host Microbe 23:302-311.e3
Yzaguirre, Amanda D; Howell, Elizabeth D; Li, Yan et al. (2018) Runx1 is sufficient for blood cell formation from non-hemogenic endothelial cells in vivo only during early embryogenesis. Development 145:
Liu, Xiaojing; Cooper, Daniel E; Cluntun, Ahmad A et al. (2018) Acetate Production from Glucose and Coupling to Mitochondrial Metabolism in Mammals. Cell 175:502-513.e13
Perales-Puchalt, Alfredo; Perez-Sanz, Jairo; Payne, Kyle K et al. (2018) Frontline Science: Microbiota reconstitution restores intestinal integrity after cisplatin therapy. J Leukoc Biol 103:799-805
Schwartz, Gregory W; Petrovic, Jelena; Zhou, Yeqiao et al. (2018) Differential Integration of Transcriptome and Proteome Identifies Pan-Cancer Prognostic Biomarkers. Front Genet 9:205
Friedman, Elliot S; Bittinger, Kyle; Esipova, Tatiana V et al. (2018) Microbes vs. chemistry in the origin of the anaerobic gut lumen. Proc Natl Acad Sci U S A 115:4170-4175
Fraietta, Joseph A; Lacey, Simon F; Orlando, Elena J et al. (2018) Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 24:563-571

Showing the most recent 10 out of 290 publications